DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Biphasic Mesothelioma — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBiphasic Mesothelioma maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for biphasic mesothelioma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BRCA1 associated deubiquitinase 1 (BAP1) — BAP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8H1T · 3.0 Å · ligand none (apo structure). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Thoracic Cancer · 2012 · 6 citations · open access
Localized biphasic type malignant mesothelioma arising in the peritoneum: Report of a case
AbstractThis report describes a rare case of localized malignant biphasic (mixed epithelioid and sarcomatoid) mesothelioma arising in the peritoneum. A 69-year-old male with a history of asbestos exposure, complaining of a painful mass in the left chest wall, was found via computed tomography (CT) to have a tumor in the left peritoneum. The resected tumor was histologically and immunohistochemically consistent with a malignant mesothelioma with mixed epithelioid and sarcomatoid type and no distant metastasis. The diagnosis of localized malignant biphasic mesothelioma arising in the peritoneum was appropriate because there was no evidence of any other primary tumor.
OncoTargets and Therapy · 2024 · 0 citations · open access
Intrapulmonary Biphasic Mesothelioma Misdiagnosed as Adenocarcinoma: Case Report and a Potential Diagnostic Pitfall
AbstractBackground: Mesothelioma is an uncommon malignant tumor with variable clinical presentations, radiological features, and morphological patterns. Mesothelioma with predominantly intrapulmonary growth presents with an insidious onset, similar radiological and even morphological features to lung cancer, and poses a diagnostic pitfall. Case Presentation: Herein, we reported a 53-year-old female with biphasic mesothelioma misdiagnosed as poorly differentiated adenocarcinoma with focal sarcomatoid carcinoma. Computed tomography (CT) scan of the chest at the first visit revealed a solid lobulated nodule in the basal segment of the lower lobe of the right lung, which was suspicious of lung cancer. Microscopically, the tumor was composed of epithelioid and spindle cells, both of which were diffusely and strongly positive for CK7, and negative for TTF-1, Napsin A, P40, Melan A, S-100, SMA, and CD34. It was originally misdiagnosed as poorly differentiated adenocarcinoma with focal sarcomatoid carcinoma at initial presentation. Until her second admission with the discovery of a nodule in the right diaphragmatic angle, the peculiar location and biphasic component reminded us of biphasic mesothelioma. Immunohistochemically, tumor cells in both pulmonary and diaphragmatic nodules were positive for calretinin, D2-40, and WT-1, but negative for BerEP4 and MOC31. The patient was treated with a chemotherapy regimen of pemetrexed and carboplatin. After 11 months of follow-up, the patient recovers well without recurrence or metastasis. Conclusion: Mesothelioma with predominantly intrapulmonary growth is extremely rare and poses a diagnostic pitfall. For this entity, subtle morphological features, selection of immunohistochemical markers, and electron microscopy are of great significance for definite diagnosis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
